Common definitions and criteria for metabolic syndrome. by Junyin Pan (20700411)

Subjects:

Assessment of study bias in the included research. by Junyin Pan (20700411)

Subjects:

Summary of subgroup analysis results. by Junyin Pan (20700411)

Subjects:

Original study data. by Junyin Pan (20700411)

Subjects:

Results of the effect of dietary anthocyanins on health outcomes, including effect size and heterogeneity analysis. by Junyin Pan (20700411)

Subjects:

Forest plot. by Junyin Pan (20700411)

Subjects:

Risk of bias assessment for eligible randomized controlled trials. by Junyin Pan (20700411)

Subjects:

S2 File - by Junyin Pan (20700411)

Subjects:

Funnel plot. by Junyin Pan (20700411)

Subjects:

Summary of studies identified in the literature search, including studies excluded from the analysis and reasons for exclusion. by Junyin Pan (20700411)

Subjects:

The flow chart of study selection process. by Junyin Pan (20700411)

Subjects:

Data extracted from included studies for the systematic review and meta-analysis. by Junyin Pan (20700411)

Subjects:

Specifications and outcomes of clinical trial studies included in the meta-analysis. by Junyin Pan (20700411)

Subjects:

Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

KIF15 mediates the trafficking of PSD95 along microtubules. by Xiaomei He (795333)

Emotional changes in <i>Kif15</i>^<i>-/-</i> mice from adolescence to adulthood. by Xiaomei He (795333)

Frontier analysis of injuries’ burden caused by fire, heat, and hot substances from 1990 to 2021. by Shi Huang (125861)

KIF15 interacts with PSD95 and affect its localization in neuronal cytoplasm neurons of the PFC. by Xiaomei He (795333)